Compare Schlumberger NV (SLB) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schlumberger NV vs Twist Bioscience Corp — how do they compare? Schlumberger NV trades at $57.07 (market cap $84.74B), while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: Schlumberger NV is far larger — about 10.1× Twist Bioscience Corp's market cap, and Schlumberger NV pays a 2.07% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| SLB | TWST | |
|---|---|---|
Market Cap | $84.74B | $8.42B |
Sector | Energy | Health |
52-Week High | $60.10 | $153.10 |
52-Week Low | $31.72 | $24.16 |
Enterprise Value | $93.47B | $8.35B |
Dividend Yield | 2.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLB trades at $57.10, down 0.71% on the day, but remains near recent highs with a bullish technical trend. The company reported three consecutive quarterly earnings beats, with Q3 2026 expected at $0.62 EPS. Recent news highlights the $3.4 billion acquisition of Kelvion, expanding SLB's data center cooling business. Revenue for 2025 was $35.71 billion with a net income margin of 8.53%, though margins have softened from prior years. Analyst consensus is strongly bullish with an average price target of $63.00.
The outlook for SLB is positive, driven by strategic diversification into data centers and solid operational cash flow near $6.5 billion annually. Key risks include exposure to oil price volatility and integration challenges from the Kelvion deal. With 85% of analysts rating it a buy, the stock offers upside potential but requires monitoring of execution on new growth initiatives.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
